Clinical trials: Rocuronium
Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery, Reversing Rocuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery
A Dose-Finding Study of Amogammadex Sodium for Reversing Vecuronium and Rocuronium-Induced Neuromuscular Blockade
Background context: Amogammadex sodium has completed Phase I-III clinical studies in China for reversal of rocuronium-induced blockade. No clinical studies have yet been conducted for vecuronium-induced blockade.
- Trial name
- NCT07595393
- Testing
- Rocuronium (0.6mg/kg), vecuronium bromide (0.1mg/kg)
- Volunteers
- 64 people
- Sponsor
- Amckaus PTY LTD.